Barrett's esophagus screening

Jump to navigation Jump to search

Barrett's Esophagus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Barrett's Esophagus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Barrett's esophagus screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Barrett's esophagus screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Barrett's esophagus screening

CDC on Barrett's esophagus screening

Barrett's esophagus screening in the news

Blogs on Barrett's esophagus screening

Directions to Hospitals TreatingBarrett's esophagus

Risk calculators and risk factors for Barrett's esophagus screening

Barret's esophagus is a major risk factor for development of esophageal adenocarcinoma. After diagnosis, regular surveillance is needed based on the grade of dyaplasia.

Overview

  • Weak recommendation, moderate-quality evidence: screening in patients with multiple risk factors for esophageal adenocarcinoma:
  1. Age: > 50 years old
  2. Sex: male
  3. Race: white
  4. Other: chronic GERD, hiatal hernia, elevated BMI (body mass index),and intraabdominal distribution of body fat.
  • Strong recommendation, low-quality evidence:
  1. Recommend against screening general population with GERD and no risk factors.[1]

Surveillance

Weak recommendation, moderate-quality evidence: Endoscopic surveillance in patients with Barrett's esophagus The following intervals are recommended:

  • No dysplasia: 3–5 years.
  • Low-grade dysplasia: 6–12 months.
  • High-grade dysplasia in the absence of eradication therapy: 3 months.[1]

References

  1. 1.0 1.1 Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. Unknown parameter |month= ignored (help)

Template:WH Template:WS